SCHEMBL495797

SCHEMBL495797

O=C(O)c1ccc(Cl)nc1NC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
CISD1 Q9NZ45 1/20 0.43
GAA P10253 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA13 Q8N1Q1 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
MAPK8 P45983 2/20 0.43
HCAR3 P49019 2/20 0.42
SYK P43405 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4402475 0.95 SYK (0.45) KMT2ACISD1GAACA12CA1
SCHEMBL16878622 0.92 HCAR3 (0.41) HCAR3SYKCSNK2A2CSNK2BCSNK2A1
SCHEMBL12936321 0.85 RIPK1 (0.49) MAPK8SYKL3MBTL1ALDH1A1MERTK
SCHEMBL22860320 0.83 RIPK1 (0.47) MAPK8SYKL3MBTL1ALDH1A1MERTK
SCHEMBL496548 0.82 MAPK8 (0.43) KMT2AGAAMAPK8HCAR3SYK
SCHEMBL6644500 0.82 CHRM3 (0.44) KMT2AMAPK8HCAR3SYKMEN1
SCHEMBL4402470 0.82 SYK (0.56) MAPK8SYK
SCHEMBL18341562 0.81 SLC6A12 (0.35) MAPK8HCAR3SYKCSNK2A2CSNK2B
SCHEMBL496019 0.80 NR2F2 (0.53) KMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL4406621 0.80 SYK (0.46) MAPK8SYKL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 KMT2A 2104/4885CISD1 1671/4885GAA 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.